Downloads: 58

Files in This Item:
File Description SizeFormat 
jdi.12773.pdf422.31 kBAdobe PDFView/Open
Title: Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation
Authors: Usui, Ryota  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-4641-0158 (unconfirmed)
Sakuramachi, Yui
Seino, Yusuke
Murotani, Kenta
Kuwata, Hitoshi
Tatsuoka, Hisato  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-0669-6825 (unconfirmed)
Hamamoto, Yoshiyuki
Kurose, Takeshi
Seino, Yutaka
Yabe, Daisuke  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-5334-7687 (unconfirmed)
Author's alias: 矢部, 大介
Keywords: β‐Cell function
Basal insulin
Liraglutide
Issue Date: Jul-2018
Publisher: Wiley
Journal title: Journal of Diabetes Investigation
Volume: 9
Issue: 4
Start page: 822
End page: 830
Abstract: Aims/Introduction: The glucose‐lowering effects of the glucagon‐like peptide‐1 receptor agonist, liraglutide, have been shown to rely on remaining β‐cell function. However, the possible associations of remaining β‐cell function with the glucose‐lowering effects of liraglutide in combination with basal insulin remain unknown and warrant investigation. Materials and Methods: This was a single‐center, retrospective, observational study carried out in a private hospital in Osaka, Japan. Type 2 diabetes patients who received a prescription change from insulin therapy, both multiple‐dose insulin and basal insulin‐supported oral therapy, to liraglutide and basal insulin combination and continued the therapy for 54 weeks without additional oral antidiabetic drugs or bolus insulin were retrospectively analyzed. Results: Among the 72 participants who received a prescription change from multiple‐dose insulin and basal insulin‐supported oral therapy to liraglutide and basal insulin combination, 57 continued the therapy for 54 weeks. Of those who continued the therapy without receiving additional oral antidiabetic drugs or bolus insulin, seven participants achieved glycated hemoglobin < 7.0% at 54 weeks, but 30 participants did not. The participants who achieved glycated hemoglobin < 7.0% at 54 weeks had a significantly higher C‐peptide immunoreactivity index, a β‐cell function‐related index frequently used in Japanese clinical settings. The receiver operating curve analysis showed that the C‐peptide immunoreactivity index cut‐off value for the achievement of glycated hemoglobin <7.0% at 54 weeks is 1.103. Conclusions: The current findings show that the glucose‐lowering effects of liraglutide rely on remaining β‐cell function, even when used with basal insulin; and suggest that liraglutide and basal insulin combination might require additional bolus insulin to fully compensate insulin insufficiency in individuals with reduced β‐cell function.
Rights: © 2017 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
URI: http://hdl.handle.net/2433/236655
DOI(Published Version): 10.1111/jdi.12773
PubMed ID: 29106046
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.